Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)

NCT06745323 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06745323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06745323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 26, 2025
Completion date
August 10, 2029
Enrollment
252 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer (sclc)